Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 1)

Next Previous
Trial Profile

A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 1)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CBL-514 (Primary)
  • Indications Cellulite
  • Focus Therapeutic Use
  • Sponsors Caliway Biopharmaceuticals

Most Recent Events

  • 25 Apr 2024 Primary endpoint has been met (Evaluation of the improvement of edematous fibrosclerotic panniculopathy (EFP) measured by cellulite severity scale from baseline following administration of 1 course of CBL-514) , according to Results published in a Caliway Biopharmaceuticals media release
  • 25 Apr 2024 Results published in a Caliway Biopharmaceuticals media release.
  • 25 Apr 2024 According to a Caliway Biopharmaceuticals media release, topline results of CBL-0201EFP Phase 2 study, which met all the primary and secondary efficacy endpoints in the ITT (Intent-to-treat) and PP (per-protocol) analysis population.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top